<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37890484</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-6711</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>Stem cell reports</Title><ISOAbbreviation>Stem Cell Reports</ISOAbbreviation></Journal><ArticleTitle>Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims.</ArticleTitle><Pagination><StartPage>2010</StartPage><EndPage>2015</EndPage><MedlinePgn>2010-2015</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2023.09.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-6711(23)00374-0</ELocationID><Abstract><AbstractText>We identified 38 businesses advertising purported stem cell interventions and exosome products for COVID-19. These companies operated or facilitated access to 60 clinics. More than 75% of these clinics were based in the United States and Mexico. Thirty-six of the businesses marketed their stem cell and exosome products as treatments for Long COVID, six advertised them as "immune boosters," five claimed to treat patients in the acute infection phase, and two claimed their products were preventive. The least expensive product cost $2,950, the most expensive was $25,000, and the average listed cost for patients was $11,322. The promotion of these products is concerning because they have not been approved by national regulators and do not appear to be supported by convincing safety and efficacy data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Leigh</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Program in Public Health, University of California, Irvine, 653 E. Peltason Drive, 2nd Floor, Irvine, CA 92697-3957, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA; Department of Family Medicine, University of California, Irvine, Irvine, CA, USA. Electronic address: leigh.turner@uci.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Juan Ramon</ForeName><Initials>JR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Program in Public Health, University of California, Irvine, 653 E. Peltason Drive, 2nd Floor, Irvine, CA 92697-3957, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najjar</LastName><ForeName>Shemms</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Program in Public Health, University of California, Irvine, 653 E. Peltason Drive, 2nd Floor, Irvine, CA 92697-3957, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajapaksha Arachchilage</LastName><ForeName>Thevin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Program in Public Health, University of California, Irvine, 653 E. Peltason Drive, 2nd Floor, Irvine, CA 92697-3957, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jia Chieng</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Program in Public Health, University of California, Irvine, 653 E. Peltason Drive, 2nd Floor, Irvine, CA 92697-3957, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Reports</MedlineTA><NlmUniqueID>101611300</NlmUniqueID><ISSNLinking>2213-6711</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000329" MajorTopicYN="N">Advertising</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040541" MajorTopicYN="N">Marketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests L.T., on a pro bono basis, wrote an expert report and testified in court for a class action lawsuit filed against a business alleged to have marketed unproven "stem cell"-based interventions. In a separate criminal case involving the sale of purported stem cell-based intervention as a treatment for COVID-19, L.T. served as a compensated expert witness for the US Department of Justice. L.T. is a member of the International Society for Stem Cell Research and serves as a member of its Ethics Committee. L.T. is a member of the International Society for Cell and Gene Therapy, and serves as a member of its Ethics Committee.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>17</Day><Hour>15</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>28</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>27</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37890484</ArticleId><ArticleId IdType="pmc">PMC10679647</ArticleId><ArticleId IdType="doi">10.1016/j.stemcr.2023.09.015</ArticleId><ArticleId IdType="pii">S2213-6711(23)00374-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bramstedt K.A. Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters. Ther. Innov. Regul. Sci. 2021;55:239&#x2013;244. doi: 10.1007/s43441-020-00224-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43441-020-00224-1</ArticleId><ArticleId IdType="pmc">PMC7528445</ArticleId><ArticleId IdType="pubmed">33001378</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies M. Long covid patients travel abroad for expensive and experimental &#x201c;blood washing. BMJ. 2022;378:o1671. doi: 10.1136/bmj.o1671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1671</ArticleId><ArticleId IdType="pubmed">35820689</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C., Collins L.F., Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020;324:1723&#x2013;1724. doi: 10.1001/jama.2020.19719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Freckelton Qc I. COVID-19: Fear, quackery, false representations and the law. Int. J. Law Psychiatry. 2020;72 doi: 10.1016/j.ijlp.2020.101611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijlp.2020.101611</ArticleId><ArticleId IdType="pmc">PMC7351412</ArticleId><ArticleId IdType="pubmed">32911444</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh J.S., Ericson J.E., Ssentongo P., Chinchilli V.M. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw. Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury M., Rocco P.R.M., Phinney D.G., Krampera M., Martin I., Viswanathan S., Nolta J.A., LeBlanc K., Galipeau J., Weiss D.J. Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. Cytotherapy. 2020;22:602&#x2013;605. doi: 10.1016/j.jcyt.2020.04.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2020.04.089</ArticleId><ArticleId IdType="pmc">PMC7163352</ArticleId><ArticleId IdType="pubmed">32933835</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury M., Ikonomou L., Dominici M., LeBlanc K., Levine B.L., Weiss D.J. The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products? Stem Cells Dev. 2021;30:119&#x2013;127. doi: 10.1089/scd.2020.0122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2020.0122</ArticleId><ArticleId IdType="pubmed">33307968</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Caputi T.L., Dredze M., Kesselheim A.S., Ayers J.W. Internet Searches for Unproven COVID-19 Therapies in the United States. JAMA Intern. Med. 2020;180:1116&#x2013;1118. doi: 10.1001/jamainternmed.2020.1764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.1764</ArticleId><ArticleId IdType="pmc">PMC7191468</ArticleId><ArticleId IdType="pubmed">32347895</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachul C., Marcon A.R., Collins B., Caulfield T. COVID-19 and &#x2019;immune boosting&#x2019;on the internet: a content analysis of Google search results. BMJ Open. 2020;10:e040989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592272</ArticleId><ArticleId IdType="pubmed">33109677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipp D., Caulfield T., Kaye J., Barfoot J., Blackburn C., Chan S., De Luca M., Kent A., McCabe C., Munsie M., et al. Marketing of unproven stem cell-based interventions: A call to action. Sci. Transl. Med. 2017;9 doi: 10.1126/scitranslmed.aag0426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aag0426</ArticleId><ArticleId IdType="pubmed">28679655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran A., Sheikhan N.Y., Sheikhan T., Nowak D.A., Witek T.J., Jr. Unsubstantiated health claims for COVID-19 infections are led by cannabidiol: return of snake oil medicine. J.&#xa0;Cannabis Res. 2021;3:49. doi: 10.1186/s42238-021-00109-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42238-021-00109-6</ArticleId><ArticleId IdType="pmc">PMC8651501</ArticleId><ArticleId IdType="pubmed">34876238</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner L. Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed &#x201c;Stem Cell Treatments&#x201d; for COVID-19. Cell Stem Cell. 2020;26:806&#x2013;810. doi: 10.1016/j.stem.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7203029</ArticleId><ArticleId IdType="pubmed">32464095</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner L. The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions. Cell Stem Cell. 2021;28:1891&#x2013;1895. doi: 10.1016/j.stem.2021.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.10.008</ArticleId><ArticleId IdType="pubmed">34739831</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner L., Munsie M., Levine A.D., Ikonomou L. Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic. Stem Cell Rep. 2021;16:2567&#x2013;2576. doi: 10.1016/j.stemcr.2021.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.09.005</ArticleId><ArticleId IdType="pmc">PMC8516140</ArticleId><ArticleId IdType="pubmed">34653406</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>